Email to a Colleague
Medscape Conference Coverage, based on selected sessions at the:
EuroPCR 2004, the Paris Course on Revascularization
May 25 - 28, 2004, Paris, France

Author: Luis Gruberg, MD

This activity is not sanctioned by, nor a part of, EuroPCR 2004, the Paris Course on Revascularization.


Content
Clinical Trials Update
TAXUS VI: A Randomized Trial of Moderate-Rate-Release, Polymer-Based, Paclitaxel-Eluting Stent for the Treatment of Longer Lesions - 9-Month Clinical Results
TAXUS stent shows safety and efficacy in patients with complex lesions. Use of the stent was associated with significant reductions in TVR and TLR compared with control.
ENDEAVOR I: Safety and Efficacy of the ABT-578-Coated Endeavor Stent -- 12-Month Follow-up
The results documenting the safety and efficacy of the Endeavor stent system at 4 months remained consistent out to 12 months, with a low rate of adverse events.
ARTS II: Arterial Revascularization Therapies Study Part II -- Sirolimus-Eluting Bx Velocity Stent for the Treatment of Multivessel de Novo Coronary Artery Lesions
Compared with standard PCI or CABG surgery, preliminary results of the ARTS II trial suggest drug-eluting stents are a viable treatment option in patients with multivessel disease.
TROPICAL: Treatment of Patients With an In-stent Restenotic Native Coronary Artery Lesion
Should drug-eluting stents replace brachytherapy as the gold standard for the treatment of in-stent restenosis? Looks like that might just need to be the case.
SVELTE: Study in Patients with De Novo Coronary Artery Lesions in Small Vessels Treated With the Cypher Stent
Expanding indications for use -- study results demonstrate effectiveness of sirolimus-eluting stents for the treatment of long lesions in small vessels.
SICTO: Sirolimus-eluting Stent In Chronic Total Occlusion
Preliminary results suggest patients with chronic total occlusions benefit from sirolimus-eluting stent placement.
PISCES: Paclitaxel In-Stent Controlled Elution Study
New stent platform shows promise and preliminary results suggest an optimal dosing strategy for the paclitaxel-eluting stent system.
IMPRESS-2 MVD: Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation Study in Patients With Multivessel Disease
Oral prednisone may be a convenient alternative to drug-eluting stents for controlling the inflammation that leads to restenosis in patients with multivessel disease.
ISAR: Individualized Drug-Eluting Stent System to Abrogate Restenosis Individualized Drug-Eluting Stent System to Abrogate Restenosis
Will on-site coating of drug-eluting stents in the cath lab help individualize treatment on a per-patient basis?
First-In-Man Studies With New Drug-Eluting Stents
SPIRIT First: Everolimus-Eluting Durable Polymer on the ML VISION Platform
First-in-man experience with new everolimus-eluting coronary stent system suggests it is safe, but the results are still preliminary.
JUPITER I: First-in-Man Experience With the Tacrolimus-Eluting JANUS CarboStent
Although the tacrolimus-eluting stent was not associated with any MACE at 30-day follow-up, patients with diabetes had a significantly higher rate of TLR at 6 months than nondiabetic patients.
STEALTH I: Stent Eluting A9 Biolimus Trial in Humans
Too early to tell? Preliminary results suggest potential effectiveness of new Biolimus A9-eluting stent
Bioabsorbable Magnesium-Alloy Stent for Below-the-Knee Lesions
Very early results demonstrate safety and efficacy of a bioabsorbable stent that degrades over a period of 2-3 months for the treatment of below-the-knee lesions.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the EuroPCR 2004, the Paris Course on Revascularization. These materials and the related activity are not sanctioned by the EuroPCR 2004, the Paris Course on Revascularization or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2004 Medscape.

 
WebMD
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.